One of our recent large earlyphase projects was a study on a biosimilar for the management of arthritis.
We’ve been observing a growing interest from sponsors in this area. Biosimilars are already widely used and accepted in Europe, and will eventually start penetrating the market due to growing availability to real-world data on long term safety and efficacy of biosimilars.
